Metformin Administration Protects Against Deltoid Tendon Damage Through Activation of Notch Signaling
Abstract
Type 2 Diabetes Mellitus (T2DM) is a growing global health concern that is associated with severe complications including diabetic tendinopathy. In this study, we found that T2DM patients had a significantly higher prevalence of tendon surgery compared to non-T2DM patients, which were alongside impaired ECM and cell adhesion. Notably, metformin-treated T2DM patients had a lower prevalence of tendon surgery compared to other medications, along with improved tendon fiber structure, downregulation of tendon damage marker MMP3, and upregulation of HES1, a Notch signaling effector gene. Metformin also activates Notch signaling in cultured tenocytes, and tendons from diabetic mice and aged monkey. These findings highlight metformin's potential to protect tendons by activating Notch signaling, offering novel insights into its therapeutic benefits beyond glucose regulation.
How strong is the evidence?
Evidence Hub reads this as a editorial / letter, done in animal, not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.